Slide 1: Welcome to the Q2 2021 Financial Results Webcast
1 Welcome to the Q2 2021 Financial Results Webcast NNIT A/S August 12, 2021 1
Slide 2: Representing NNIT A/S today
Representing NNIT A/S today Pär Fors Pernille Fabricius Chief Executive Officer Chief Financial Officer 2
Slide 3: Agenda
Agenda 01 Highlights for Q2 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2021 05 Closing remarks 3
Slide 4: Forward-looking statements
Forward-looking statements This announcement contains forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar me
Slide 5: Agenda
Agenda 01 Highlights for Q2 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2021 05 Closing remarks 5
Slide 6: New CEO to drive continued international development and growth
New CEO to drive continued international development and growth Continued rollout of Continued growth in Continued Winning strategy launched Life Sciences Solutions momentum in 2020 International 6
Slide 7: Pär Fors
Pär Fors Profile • 30+ years of experience working within IT • 20+ years of executive experience, leading IT teams to success • IT generalist with pockets of deep knowledge Background • CEO of CGI Scandinavia • Chairman of the Swedish IT and Telecom Industries • MSc in Business Administration and Ec
Slide 8: Commercial Highlights Q2 2021
Commercial Highlights Q2 2021 NNIT secured substantial infrastructure business with Novo Nordisk for another five years… Amount Contract Segment Customer (DKK Length million) (years) Renewal of a global IT infrastructure agreement with the Existing Medium Life Sciences 5 Novo Nordisk Group Customer
Slide 9: Acquisition #4
Acquisition #4 Further expanding the NNIT portfolio of services to the international life sciences market 9
Slide 10: NNIT Life Sciences Acquisition Milestones
NNIT Life Sciences Acquisition Milestones 2018 2019 2020 2021 NNIT acquires US- NNIT acquires Swiss- NNIT acquires US- NNIT acquires Irish- based IT software based IT compliance based supply-chain based and migration and quality and compliance Pharmaceutical consulting company, management consulting
Slide 11: Strategic Rationale
Strategic Rationale Pharmaceutical production is one of SL Controls’ the most important production equipment The acquisition will life sciences growth integration services expand NNIT’s areas with an annual are complementary to offerings within the growth rate of 14.2%. NNIT’s offerings strategic pr
Slide 12: Agenda
Agenda 01 Highlights for Q2 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2021 05 Closing remarks 12
Slide 13: Q2 2021 & 1H 2021 at a glance
Q2 2021 & 1H 2021 at a glance Revenue Winning solutions Operating profit* Investment level** DKK 710m DKK 368m DKK 36m DKK 19m Q2 2021 1.3% growth 52% 5.1% 2.7% -1.8% organic growth % of revenue operating profit margin % of revenue Revenue Winning solutions Operating profit* Investment level** DKK 1
Slide 14: Group Performance Overview
Group Performance Overview Q2 2021 First half 2021 Full Year 2020 DKK million Q2 2021 Q2 2020 Change 6M 2021 6M 2020 Change 2020 Revenue 710 701 1.3% 1,441 1,423 1.3% 2,830 Cost of goods sold 624 608 2.6% 1,255 1,227 2.3% 2,443 Gross profit 86 93 -7.5% 186 196 -5.1% 387 Gross profit margin 12.1% 13.
Slide 15: Life Sciences
Life Sciences Q2 2021 First half 2021 Full Year 2020 DKK million Q2 2021 Q2 2020 Change 6M 2021 6M 2020 Change 2020 Life Sciences (excl. NNG) 234 174 34.5% 462 333 38.7% 717 Life Sciences (Int.) 165 106 55.7% 324 198 63.6% 456 Life Sciences (DK) 69 68 1.5% 138 135 2.2% 261 Novo Nordisk Group 151 175
Slide 16: Private & Public
Private & Public Q2 2021 First half 2021 Full Year 2020 DKK million Q2 2021 Q2 2020 Change 6M 2021 6M 2020 Change 2020 Enterprise 182 170 7.1% 356 376 -5.3% 712 Public 75 107 -29.9% 173 212 -18.4% 407 Finance 68 75 -9.3% 140 142 -1.4% 262 Revenue 325 352 -7.7% 669 730 -8.4% 1,381 Cost of goods sold
Slide 17: Agenda
Agenda 01 Highlights for Q2 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2021 05 Closing remarks 17
Slide 18: Balance sheet
Balance sheet Assets June 30, June 30, Dec 31, Equity and liabilities June 30, June 30, Dec 31, DKK million 2021 2020 2020 DKK million 2021 2020 2020 Intangible assets 796 527 781 Share capital 250 250 250 Tangible assets 517 557 552 Treasury shares -2 -3 -3 Lease assets 198 271 227 Retained earning
Slide 19: Cash flows
Cash flows Cash flow Dec 31, Q2 2021 Q2 2020 6M 2021 6M2020 DKK million 2020 Net profit for the period -30 14 1 49 76 Reversal of non-cash items 89 94 168 204 228 Net interest and taxes paid -10 -9 -27 -31 -58 Changes in working capital 129 131 9 91 282 Cash flow from operating activities 178 230 15
Slide 20: Agenda
Agenda 01 Highlights for Q2 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2021 05 Closing remarks 20
Slide 21: Backlog development, current year
Backlog development, current year Backlog for the year, beginning of Q3 2021 +5,4% • At the beginning of Q3 2021, NNIT’s order entry backlog for 2021 3.000 (+136) 2.691 amounted to DKK 2,643 million, up 5.4% from last year. 2.643 2.507 2.500 2.379 • Life Sciences (excl. NNG) customers increased by 4
Slide 22: Outlook
Outlook 2021 Revenue growth Reported currencies: 1-4% Operating profit margin Reported currencies: Around 5% before special items CAPEX Share of revenue: 5-7%1 1CAPEX investments and re- investments are in 2021 expected to be between 5-7 percent of total revenue excluding acquisitions 22
Slide 23: Agenda
Agenda 01 Highlights for Q2 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2021 05 Closing remarks 23
Slide 24: Closing remarks
Closing remarks Momentum within Life Sciences Winnings Solutions Expectations for 2021 International continued that now constitute 52% remain, and we maintain the strong growth in Q2 of total revenue our financial guidance 2021 with revenue increasing 56% compared to Q2 2020 Strategy established to
Slide 25: Questions
Questions ANIT
Slide 26: Investor contact information
Investor contact information Upcoming events Investor contact November 3, 2021 • Interim report for the first nine months of 2021 Pernille Fabricius Chief Financial Officer +45 3077 9500 PNFA@nnit.com 26
Slide 27: We make a mark
We make a mark nnit.com ANIT